# Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Source: https://onco.cc/trials/nct05961839/  
OnCo record `nct05961839` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of SGR-2921 run by Schrödinger, Inc., terminated.

## Summary

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome is a phase 1 interventional study registered as NCT05961839 by Schrödinger, Inc., with 66 participants enrolled, started 2023-09-27. Conditions recorded: Acute Myeloid Leukemia and High-Risk and Very High-Risk Myelodysplastic Syndromes. Interventions recorded: SGR-2921.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05961839
- Phase: 1
- Setting: A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Sponsor: Schrödinger, Inc.
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT05961839: https://clinicaltrials.gov/study/NCT05961839

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Higher-risk myelodysplastic syndromes](https://onco.cc/cancers/mds-higher-risk/)
- drugs: [SGR-2921](https://onco.cc/drugs/sgr-2921/)
- companies: [Schrödinger](https://onco.cc/companies/schrodinger/)

---
JSON: https://onco.cc/api/v1/entities/nct05961839.json